Literature DB >> 35950381

[Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma].

X Dai1, F Wang1, Y Q DU1, Y X Song1, T Xu1.   

Abstract

OBJECTIVE: To investigate the correlation between expression levels of adipokine and clinicopathological features and prognosis of patients with upper tract urothelial carcinoma (UTUC) based on immunohistochemical staining and bioinformatics analysis.
METHODS: The 8 adipokines in this study included adiponectin (AdipoQ), leptin (LEP), interleukin (IL)-6, IL-10 and their receptors (AdipoR1, AdipoR2, LEPR, IL-6R, IL-10RA, IL-10RB). Tissue samples of patients with UTUC who underwent surgical treatment in Peking University People's Hospital from January 2014 to April 2021 were selected for immunohistochemical staining. Their quantitative gene expression data were calculated by H-Score, and relevant clinical and follow-up data were collected retrospectively. Transcription group sequencing data of UTUC patients in Gene Expression Omnibus database (GSE134292 dataset) were downloaded for comparison. Chi-square test or t-test was used to compare the expression level of adipokine between non-muscle invasive group and muscle invasive group. Univariate and multivariate Cox regression analysis and Kaplan-Meier survival curve were utilized to analyze independent predictors of overall survival (OS), disease-free survival (DFS), intravesical recurrence-free survival (IVRFS) in the both cohorts. The P < 0.05 was considered statistically significant.
RESULTS: In the study, 63 tissue samples of the patients with UTUC who underwent surgical treatment in Peking University People's Hospital and 57 UTUC patients in GSE134292 dataset were selected. In immunohistochemical cohort, the expressions of AdipoQ (P=0.003 6), AdipoR1 (P=0.006 5), LEP (P=0.007 7), IL-10 (P=0.006 9), and IL-10RA (P=0.008 9) were statistically higher in muscle invasive group. In GSE134292 cohort, the expressions of AdipoR1 (P=0.000 4), AdipoR2 (P=0.000 4), IL-6 (P=0.005 0), IL-10 (P=0.001 7), and IL-10RA (P=0.008 1) were statistically higher in muscle invasive group. Kaplan-Meier survival curve and multivariate Cox regression analysis showed that high IL-10RA expression was an independent predictive factor of IVRFS (P=0.044, HR=0.996, 95%CI: 0.992-0.998) in immunohistochemical cohort, which was confirmed in GSE134292 cohort (P=0.014, HR=0.515, 95%CI: 0.304-0.873).
CONCLUSION: The expression levels of AdipoQ, AdipoR1, IL-10, and IL-10RA were correlated with tumor stage, suggesting that these adipokines played important roles in tumor progression. IL-10RA was an independent predictor of IVRFS, suggesting that IL-10 and its receptor played a critical role in tumor recurrence.

Entities:  

Keywords:  Adipokine; Immunohistochemical; Upper tract urothelial carcinoma

Mesh:

Substances:

Year:  2022        PMID: 35950381      PMCID: PMC9385515     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  23 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 2.  Multifaceted roles of adiponectin in cancer.

Authors:  Lionel Hebbard; Barbara Ranscht
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-11-22       Impact factor: 4.690

3.  Adiponectin receptor expression in human malignant tissues.

Authors:  Sharon H Chou; Sofia Tseleni-Balafouta; Hyun-Seuk Moon; John P Chamberland; Xiaowen Liu; Nikolaos Kavantzas; Christos S Mantzoros
Journal:  Horm Cancer       Date:  2010-06       Impact factor: 3.869

4.  Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

Authors:  Eek Joong Park; Jun Hee Lee; Guann-Yi Yu; Guobin He; Syed Raza Ali; Ryan G Holzer; Christoph H Osterreicher; Hiroyuki Takahashi; Michael Karin
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

Review 5.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

6.  Adiponectin/AdipoR1 Axis Promotes IL-10 Release by Human Regulatory T Cells.

Authors:  Patricia Ramos-Ramírez; Carina Malmhäll; Omar Tliba; Madeleine Rådinger; Apostolos Bossios
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

7.  Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.

Authors:  William L Holland; Russell A Miller; Zhao V Wang; Kai Sun; Brian M Barth; Hai H Bui; Kathryn E Davis; Benjamin T Bikman; Nils Halberg; Joseph M Rutkowski; Mark R Wade; Vincent M Tenorio; Ming-Shang Kuo; Joseph T Brozinick; Bei B Zhang; Morris J Birnbaum; Scott A Summers; Philipp E Scherer
Journal:  Nat Med       Date:  2010-12-26       Impact factor: 53.440

8.  Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.

Authors:  Qian Qian; Changping Wu; Jianping Chen; Weibing Wang
Journal:  Biomed Res Int       Date:  2020-07-16       Impact factor: 3.411

Review 9.  Adiponectin as Link Factor between Adipose Tissue and Cancer.

Authors:  Erika Di Zazzo; Rita Polito; Silvia Bartollino; Ersilia Nigro; Carola Porcile; Andrea Bianco; Aurora Daniele; Bruno Moncharmont
Journal:  Int J Mol Sci       Date:  2019-02-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.